Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLETTE: Olaparib Monotherapy vs Olaparib Combinations in Metastatic Triple Negative Breast Cancer
NCT03330847Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of ceralasertib, adavosertib in triple-negative breast cancer (TNBC), sponsored by AstraZeneca. Started Mar 2018; status: active, not recruiting.
02
Drugs
ceralasertibadavosertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03330847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330847.